Pazopanib is an orally bioavailable, ATP-competitive, multi-targeted kinase inhibitor mainly targeting VEGFR2 and PDGFR tyrosine kinases, but the biological sequences of pazopanib activities beyond anti-angiogenesis are poorly defined. We used a panel of 38 GC cell lines in order to test the efficacy of pazopanib. In a growth inhibition assay, genomic changes indicated 
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INTRODUCTION
Gastric cancer (GC) is the leading cause of cancer death worldwide with an incidence of 18.9 deaths/100,000 people per year (1) . There are approximately 934,000 new cases of GC each year worldwide, with 56% of the new cases occurring in East Asia (2) . According to Central Tumor Registry data for 2002, GC accounts for 20.8% of all cancers in Korea (3).
Although overall survival rates of GC have improved after the implementation of a national screening program in adults over 40 years old in Korea, a large proportion of patients are still diagnosed at metastatic stages. Typically, fluoropyrimidines and platinum compounds form the backbone of chemotherapy for patients with advanced gastric cancer (AGC) and have substantially improved outcomes compared with single-agent chemotherapy or best supportive care (4) . However, the median survival time following cytotoxic chemotherapy is still less than 12 months and thus, metastatic GC remains a therapeutic challenge for medical oncologists. The role of molecularly targeted therapy has not been adequately explored in GC when compared to other common solid tumors such as non-small cell lung cancer, breast, or colorectal cancer.
There is increasing evidence that suggests that sensitivity to molecularly targeted agents among diverse human cancers is well correlated with underlying genetic alterations of the tumor.
Therefore, identifying critical genes that play pivotal roles in controlling tumor growth and survival will establish the basis for developing therapeutic targets. The fibroblast growth factor receptor (FGFR) tyrosine kinase family is comprised of four kinases (FGFR 1, 2, 3, and 4) that differentially respond to 18 FGF ligands and have long been implicated as causes of cancer (5) .
Recent research has shown that members of the FGFR family are promising targets that are deregulated by amplification, point mutation, or translocation. Amplification or activation of FGFR1 has been reported in lung cancer and translocations involving FGFR3, and activating in FGFR3 have been associated with multiple myeloma and bladder cancer. Missense mutations of FGFR2 has also identified in several types of human cancer including lung squamous carcinoma, gastric cancer and endometrial cancer (6) (7) (8) . These cancers are shown to be sensitive to FGFR2 kinase inhibition in the cell lines bearing such FGFR2 mutations, implicating FGFR2 as a novel therapeutic target (7) . In GC, FGFR2 was first identified as the K-sam gene amplification in the human GC cell line KATO-III, and is preferentially amplified or overexpressed in poorly differentiated or undifferentiated types of GCs (9, 10). Recent preclinical studies have demonstrated a critical role for FGFR2 amplification in GC cell proliferation and survival, and detected anti-tumor activities of multi-targeted TKIs and pan-FGFR inhibitors in FGFR2 amplified GC cell lines, which suggests that FGFR2 amplification may be a promising therapeutic target in GC (11) (12) (13) (14) (15) . Therefore, the present preclinical study primarily focused on the antitumor activities of pazopanib on FGFR2 signaling in GC.
METHODS
Cell culture, cell growth assay, and colony formation assay Thirty-eight genetically defined human GC cell lines representing broad genetic heterogeneity were assembled to establish an in vitro platform that could be used to potentially cell lines & NIH 3T3 lines were maintained in DMEM (Gibco-BRL, Carlsbad, CA, USA) and supplemented with 10% heat-inactivated FBS, 100 units/mL penicillin, 100 units/mL streptomycin, and 2 mM glutamine. The other cell lines were cultured in RPMI-1640 medium (Gibco-BRL) and supplemented with 10% heat-inactivated FBS, 100 units/mL penicillin, 100 units/mL streptomycin, and 2 mM glutamine. All cells were incubated in a humidified atmosphere containing 5% CO 2 at 37°C. All cell lines have been authenticated using viability, morphology and growth curve analysis on a regular basis, and tested negative for mycoplasma. Colonies, defined as groups of cells containing a minimum of 50 cells, were stained with 0.1% crystal violet and counted under an inverted phase contrast microscope CKX31SF (Olympus Biosystems, Hamburg, Germany). Colonies were photographed after two weeks and the percent relative number of colonies was expressed as (number of colonies from treated cells/number of colonies from controls) × 100. The assay was repeated three times with duplicate samples.
DNA Sequencing for FGFR2
Analysis of DNA sequencing was performed for all known mutation sites of FGFR2 exons. DNA was extracted from five paraffin sections of 10 μm thickness containing a representative portion of each tumor block, using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany). One hundred nanograms of DNA were amplified in a 20 μL reaction solution containing 2 μL of 10X buffer (Roche, Mannheim, Germany), 1.7 to 2.5 mmol/L of MgCl 2 , 0.3μM of each primer pairs, 250 μM of deoxynucleotide triphosphate, and 2.5 units of DNA polymerase (Roche). Amplifications were performed using a 5-minute initial denaturation at 94℃; followed by 30 cycles of 1 minute at 94℃, 1 minute at 55℃, and 1 minute at 72℃, and a 10-minute final extension at 72℃. Polymerase chain reaction (PCR) products were then 2% gelpurified with a QIAgen gel extraction kit (Qiagen). DNA templates were processed for the DNA sequencing reaction using the ABI-PRISM BigDye Terminator version 3.1 (Applied Biosystems, Foster City, CA, USA) with both forward and reverse sequence-specific primers. Twenty nanograms of purified PCR products were used in a 20μL sequencing reaction solution containing 8 μL of BigDye Terminator v3.1 and 0.1 μM of the same PCR primer. Sequencing reactions were performed using 25 cycles of 10 seconds at 96℃, 5 seconds at 50℃, and 4 minutes at 60℃. Sequence data were generated with the ABI PRISM 3100 DNA Analyzer 
Immunoprecipitation (IP), western blot analysis and RTK array
Cells grown under the previously specified conditions were lysed in the following lysis 
Fluorescence activated cell sorting (FACS) for cell cycle analysis
The FACS analysis was performed using methods similar to those described previously.
Briefly, 1-1.5 × 10 6 cells were seeded into 10 cm 3 plates, and the drugs were added 24 h later.
After 24 h of treatment, the cells were trypsinized and fixed overnight in ethanol at 4°C. Inc., Topsham, ME, USA). All experiments were repeated three times.
Patients and tissue specimens
The outcomes of 544 stage II -IV (M0) GC patients who received adjuvant chemoradiation therapy after curative surgery were previously reported (17). Of these patients and an additional 23 stage IB patients who were included in a previous study, formalin-fixed paraffin-embedded primary tumor tissues were available from 482 patients. The postoperative adjuvant treatment that was adopted was the same as that used for the INT-0116 (SWOG-9008) trial (18). All patients provided written informed consent according to institutional guidelines and the study was approved by the Institutional Review Board at Samsung Medical Center, Seoul, Korea.
Statistical analyses
Disease-free survival (DFS) was defined as the time from surgery to the first relapse of cancer, or death of any cause. Overall survival (OS) was calculated from the date of surgery to the date of death. OS and DFS were calculated using the Kaplan-Meier method. Correlation analyses were performed using the two sided chi-square test or Fisher's exact test. Differences in disease-free and overall survival were compared using log-rank tests and Cox proportional hazards analysis. P values less than 0.05 were considered statistically significant. 
RESULTS

Correlation
known oncogenic FGFR2 mutations were not found in current study of the GC cell lines (data not shown) (7, 19) .
Pazopanib blocks proliferation and survival of GC cell lines with FGFR2 amplification
GC cell lines were first treated with pazopanib to investigate whether inhibition of 
Pazopanib selectively inhibits FGFR2 phosphorylation and downstream signaling molecules in FGFR2-amplified GC cell lines
The effects of drug treatment on FGFR2-dependent signaling were tested to address the mechanism by which pazopanib triggers cell death in (Figure 4 and 5B). These findings suggest that FGFR2 signaling plays a critical role in cell survival in these FGFR2-addicted cell lines.
Correlations between FGFR2 amplification and clinical outcomes
To assess FGFR2 amplification in clinical GC cases, tumor specimens from 482 AGC patients were analyzed by qPCR using TaqMan probes and dual-color FISH (Figure 6 ). Of the 482 patients, 24 (5%) of the patients had FGFR2 copy numbers greater than 4.0 copies. FISH and qPCR analyses were also consistent in identifying FGFR2 amplification in tissue specimens, with higher-fold amplification apparent by FISH ( Figure 6 ). This presumably reflects the effect 
investigated beyond PDGFRA mutations that are largely confined to GISTs (24). In an in vitro kinase assay, pazopanib had modest activity against FGFR2 kinase with nanomolar concentrations expecting anti-tumor activity in tumors having dysregulated FGFR2 signaling (21).
In this preclinical study, pazopanib sensitivity was restricted to a small number of GC cell lines harboring FGFR2 amplification. This study also showed that FGFR2 activation is coupled to critical downstream effectors such as Erk and Akt, and that disrupting these pathways seems to mediate the inhibitory effects of pazopanib on proliferation and cell survival in the FGFR2-addicted cells in vitro. Hence, these findings suggest that activated FGFR2-signaling by amplification may be a critical target, and that pazopanib might be useful as an FGFR2 inhibitor in the clinical management of the subset of tumors that exhibit FGFR2 activation. Interestingly, there was no evidence of FGFR2 mutations in 38 GC cell lines, which argues in favor of amplification rather than mutation as the preferred mechanism of FGFR2 activation in a subset of GC. In contrast, FGFR2 activation is mainly associated with oncogenic mutations in endometrial and breast cancers (7).
We found that FGFR2 amplification was also observed in a relatively small subset (5%) of GC clinical samples in this study, which is consistent with recent Japanese and Chinese study on (25, 26) . Although the frequency of FGFR2 amplification has not been well investigated in a large cohort, relatively low incidence of FGFR2 amplification in GC specimens might be a possible impediment in developing FGFR2-targeted therapeutics in GC.
Moreover, because a large-scale analysis of FGFR2 status has not been performed in gastric cancer tissues or DNA samples, the cut-off value for FGFR2 amplification or FGFR2 expression has not yet been determined. Therefore, companion diagnostics to reliably detect FGFR2 activation measured by FGFR2 amplification or FGFR2 protein expression needs to be standardized. As the growth curves for HSC-39 and SNU-16 only reach a lower limit of 40% survival in this preclinical study (Figure 2A) , it is presumed that the relatively lower level of amplification in SNU-16 & HSC-39 ( Figure 1B ) may be related to somewhat lower response to pazopanib. Therefore, a predictive role of FGFR2 amplification for treatment response according the cut-off value should be further validated as a novel therapeutic target in prospective clinical studies. In addition, given that pazopanib is less potent against the FGFRs versus the VEGFRs, it is important whether an efficacious concentration of pazopanib can be achieved in gastric cancer patients. Although no pharmacokinetic (PK) data on pazoapnib in GC patients are available, steady-state exposure plateaued at doses ≥ 800 mg/day and was ≥ 15 μg/ml (≈ 34 μM) in 93% of patients receiving a dose of 800 mg daily from PK data in a phase I study (27), which plasma concentration can be clinically achieved might be enough to block FGFRs. This C trough plasma pazopanib concentration of ≥ 15 μg/ml also appeared to correlate with clinical activity in patients with RCC, which could be effective for GC patients with All experiments were repeated three times. 
